Argonaute-2蛋白在膀胱移行上皮癌组织中的表达及其临床意义

Expression and significance of Argonaute-2 protein in bladder transitional cell carcinoma

目的研究Argonaute-2蛋白在膀胱移行上皮癌组织中的表达及临床意义。方法通过实时荧光定量PCR、免疫组化法测定88例经病理确诊的膀胱移行上皮癌患者配对的肿瘤组织、癌旁组织中Argonaute-2蛋白的表达,分析该蛋白表达与预后和其他临床病理参数的相关性。结果膀胱移行上皮癌组织中Argonaute-2 mRNA表达明显高于癌旁组织(P<0.05);Argonaute-2蛋白表达明显高于癌旁组织(P<0.05)。高表达Argonaute-2与肿瘤的病理分级、临床分期以及淋巴结转移情况显著相关。利用Kaplan-Meier生存曲线和Log-Rank检验分析显示,肿瘤组织中Argonaute-2蛋白高表达组患者的5年生存率较低表达组患者明显降低(62.2%vs.86.3%,P<0.05)。结论 Argonaute-2蛋白的异常表达可能参与膀胱移行上皮癌的发生、发展,可作为膀胱癌预后评估的一个重要生物学指标。

Objective To investigate the expression of Argonaute-2 protein in human bladder transitional cel1 carcinoma（BTCC）and the clinica1 significance.Methods Expression of Argonaute-2 protein was assessed by real-time quantitative PCR and immunohistochemistry（IHC）in the tumor tissue and adjacent non-cancer tissue from88 patients who had undergone surgery for histologically proven BTCC.The correlation with other clinico-pathologic factors were evaluated.Results The expression of Argonaute-2 mRNA and Argonaute-2 protein was significantly higher in tumor tissues than in adjacent non-cancer samples（both P0.05）.A significant correlation existed between the high expression of Argonaute-2 protein with the pathological grading,clinical stage（T）and lymph node metastasis.Survival analysis by Kaplan-Meier survival curve and log-rank test demonstrated that elevated Argonaute-2 expression in cancer tissue predicted worse overall survival（OS）compared to group with lower expression（86.3% vs.62.2%）.Conclusions The aberrant expression of Argonaute-2 in bladder transitiona1cel1 carcinoma is possibly involved with tumorigenesis and development,and the Argonaute-2 protein could act as a potential biomarker for prognosis assessment of bladder cancer.